---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-100608"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:19:50.480994+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# VIRAGE Phase 2b trial meets primary OS endpoint; VCN-01+SoC mOS 10.8 vs 8.6 months

## Summary
- VCN-01 + gem/nab-paclitaxel met primary OS endpoint in FAS: median 10.8 vs 8.6 months, HR 0.57 (p=0.034).
- PFS improved: 7.0 vs 4.6 months (HR 0.55, p=0.012) and duration of response doubled (11.2 vs 5.4 months).
- Patients receiving 2 VCN-01 doses had greater OS benefit: median 14.8 vs 11.6 months (HR 0.44).
- VCN-01 was safe and well tolerated; related SAEs were transient and resolved.
- Data support further evaluation in larger blinded trial with additional VCN-01 doses.

## SEC filing metadata
- accession: 0001104659-25-100608
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465925100608/0001104659-25-100608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465925100608/tm2529071d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-100608
- JSON: https://secwatch.observer/filing/0001104659-25-100608.json
- Plain text: https://secwatch.observer/filing/0001104659-25-100608.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.